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Enhanced oncolytic adenoviral 
production by downregulation 
of death‑domain associated protein 
and overexpression of precursor 
terminal protein
Jihyun Lee1,2,4, Geun‑Hyeok Oh1,2,4, Jeong A. Hong1,2, Soojin Choi1,2, Hye Jin Choi3* & 
Jae J. Song1,2*
Adequate viral replication in tumor cells is the key to improving the anti‑cancer effects of oncolytic 
adenovirus therapy. In this study, we introduced short hairpin RNAs against death‑domain associated 
protein (Daxx), a repressor of adenoviral replication, and precursor terminal protein (pTP), an initiator 
of adenoviral genome replication, into adenoviral constructs to determine their contributions to 
viral replication. Both Daxx downregulation and pTP overexpression increased viral production in 
variety of human cancer cell lines, and the enhanced production of virus progeny resulted in more 
cell lysis in vitro, and tumor regression in vivo. We confirmed that increased virus production by 
Daxx silencing, or pTP overexpression, occurred using different mechanisms by analyzing levels of 
adenoviral protein expression and virus production. Specifically, Daxx downregulation promoted both 
virus replication and oncolysis in a consecutive manner by optimizing IVa2‑based packaging efficiency, 
while pTP overexpression by increasing both infectious and total virus particles but their contribution 
to increased viral production may have been damaged to some extent by their another contribution 
to apoptosis and autophagy. Therefore, introducing both Daxx shRNA and pTP in virotherapy may 
be a suitable strategy to increase apoptotic tumor‑cell death and to overcome poor viral replication, 
leading to meaningful reductions in tumor growth in vivo.
Abbreviations
PBS  Phosphate buffered saline
shhDaxx  ShRNA of human Daxx
shmDaxx  ShRNA of mouse Daxx
RT-PCR  Reverse-transcriptional PCR
SDS–PAGE  Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
For many years, oncolytic virotherapy has been a promising anti-cancer gene therapeutic  strategy1. Oncolytic 
viruses (OVs) are genetically modified viruses that are able to selectively replicate and produce progeny viruses 
in cancer cells, resulting in cancer cell  lysis2. OVs can manipulate the host cellular machinery to create a favorable 
environment for the production of progeny viruses. Many previous studies have aimed to develop tumor-selective 
replication systems. E1B55K-deleted adenovirus was engineered to use p53-mediated growth arrest for selectiv-
ity in cancer cells, most of which lack functional  p533. However, there are some reports that p53 deficiency in 
cancer cells seems unlikely to be the determinant for oncolytic selectivity of E1B55K-deleted adenovirus, and 
blocking p53 activity may not be a major requirement for viral replication, or p53 could even promote adenoviral 
 replication4,5. Instead, induction of cyclin E, a requirement for adenovirus replication in the absence of E1B55K, 
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could be a molecular marker for oncolytic selectivity and means that E1B55K-like cancer factors are capable of 
cyclin E induction irrespective of p53  status6.
Adenoviral DNA replication is a very efficient process that produces approximately one million copies of 
viral DNA in infected cells within 40 h7. For adenoviral DNA replication, three viral proteins encoded by E2 
genes are required: precursor terminal protein (pTP), adenovirus DNA polymerase (Ad Pol), and DNA-binding 
protein (DBP)7. Adenoviral DNA replication starts with protein-primed DNA synthesis initiated by the covalent 
addition of a dCMP residue to an 80 kDa precursor of  pTP8. This covalent residue addition to pTP at serine 
580 provides a 3′ hydroxyl to stimulate DNA chain  extension9. The pTP/Ad Pol complex binds to the DNA core 
region and then pTP-CAT, a pTP-trinucleotide intermediate, jumps back to positions 1–3 at the beginning of 
the template strand. Shortly after this three-nucleotide jump, Ad Pol dissociates from pTP, leading to progressive 
DNA elongation. Initiation is enhanced by two cellular factors, nuclear factor I (NFI or CTF1) and nuclear fac-
tor III (NFIII or Oct1)10. Processing of pTP-DNA creates a distinct template for early transcription (TP-DNA), 
and serves to guide the template to the appropriate subcellular location throughout the course of  infection11,12.
For the purpose of viral propagation, several adenoviral gene products and host cellular factors affect or 
inactivate each other. For example, the early viral gene products E1B55K and E4orf6 associate with host cellular 
proteins, such as elongin B and C, Cullin5, and Rbx-1, to form the E3 ubiquitin ligase complex that induces 
proteasomal degradation of target proteins such as p53, integrin α3, MRE11, and RAD50 of the MRE11-RAD50-
NBS1 (MRN) complex to prevent both apoptosis prior to virus production, and host  defenses13. The highly 
conserved MRN complex is important for sensing, processing, and the repair of double-stranded breaks, and 
these repair systems counteract DNA virus  replication14.
A cellular factor known to inhibit the production of adenoviral progeny, Daxx is a multi-functional protein 
involved in transcriptional regulation, cell apoptosis, disease progression, tumorigenesis, and as an  antiviral15–17. 
Daxx is a component of promyelocytic leukemia protein nuclear bodies and a negative regulator of adenovirus 
serotype-5 replication during productive  infection18–24. Daxx cooperates with X-linked α-thalassemia retarda-
tion syndrome protein (ATRX), a putative member of the sucrose non-fermentable 2 family of ATP-dependent 
chromatin remodeling  proteins25. Daxx, in association with ATRX, is involved in histone deacetylase (HDAC) 
recruitment, H3.3 deposition, and transcriptional repression of cellular promoters. During adenovirus sero-
type-5 replication, the Daxx/ATRX complex represses virus gene-expression  efficiency25. In addition to recruiting 
HDAC in combination with ATRX, Daxx has also been reported to be a transcriptional repressor; it negatively 
regulated the transcription of a set of autophagy genes known to promote viral adenoviral replication and onco-
lysis in a time-dependent  manner26–28.
Here, we develop a way to enhance adenovirus production in many cancer cell types by modulating both viral 
and cellular factors. In this study, we used E1B55K-deficient oncolytic adenovirus armed with Daxx shRNA, pTP, 
or both, to compare virus production and tumor-cell death using various human cancer cell lines, and different 
in vivo mouse models.
Materials and methods
Cell lines. The human cancer cell lines DU-145 (human prostate adenocarcinoma), MDA-MB-231 (human 
breast cancer cell line), U251N (human glioma), PC3 (human prostate adenocarcinoma), A549 (human lung 
carcinoma), SK-Hep1 (human liver adenocarcinoma), Hep3B (hepatocellular carcinoma), and HPAC (human 
pancreatic adenocarcinoma), in addition to 293A, a subclone of the human embryonic kidney 293 cell (Invit-
rogen, Carlsbad, CA, USA), were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum 
(HyClone, Logan, UT, USA). All cells were maintained in a 37 °C humidified atmosphere containing 5%  CO2.
Reagents. Antibodies to Daxx, LC3A/B, p53 and acetyl-p53 (Lys382) were purchased from Cell Signaling 
Technology (Beverly, MA, USA). Antibodies to E1A and β-actin were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz Biotechnology Inc, Dallas, TX, USA).
3-MA, rapamycin and pan caspase Inhibitor Z-VAD-FMK were purchased from Promega (Madison, WI, 
USA). Anti-adenovirus type 5 (Ad5) antibody was purchased from Abcam (Abcam, Cambridge, UK). Antibod-
ies to IVa2, L4-22K, and L4-33K were kindly provided by Dr. Patrick Hearing at SUNY Stony Brook. Restriction 
enzymes were purchased from New England Biolabs (Ipswich, MA, USA). Trizol was purchased from Life Tech-
nologies (Carlsbad, CA, USA), and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Polyclonal antibody production of pTP. A 13-mer synthetic peptide, HNRDMTGGVFQLR, was 
selected as the epitope of pTP from among three  candidates8. Amino acid sequences were obtained from NCBI 
(NC_001405.1). Synthetic peptide was immunized into rabbits and serum obtained from the rabbits to make 
polyclonal antibodies. The overall process, including peptide synthesis, antibody production, and purification, 
were performed by Bionics (Daegeon, Korea).
Generation of oncolytic adenovirus expressing Daxx‑specific shRNA. The adenoviral shuttle vec-
tor, pSP72ΔE3-H1-shDaxx which was previously  constructed23, was linearized by XmnI digestion. The adenovi-
ral vector dl324-BstBI was linearized by SpeI digestion, and the two linearized vectors were co-transformed into 
E. coli BJ5183 cells for homologous recombination. Then dl324-BstBI-H1-shDaxx after linearization by Bsp1191 
was homologously recombined again with adenoviral shuttle vector, pVAX1-3484-CMVp-ΔE1B after lineariza-
tion by PmeI, which contains an E1 region without E1B55K, to generate E1B55K-deleted oncolytic adenovirus 
arming Daxx shRNA. The final adenoviral plasmid, dl324-3484-CMVp-ΔE1B-H1-shDaxx, was then digested 
with PacI and transfected into HEK-293 cells to generate tumor-selective replication-competent adenovirus. The 
infectious titer of the adenovirus was determined by a limiting dilution assay in 293A cells.
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Generation of pTP‑overexpressing oncolytic adenovirus. For cloning the pTP gene of the adeno-
viral genome into adenoviral shuttle vector, pVAX1-3484-CMVp-ΔE1B, total RNA was isolated from cells with 
standard Trizol/chloroform extraction following 24 h post infection with E1B55K-deleted oncolytic adenovirus. 
cDNA was synthesized by RT-PCR using random hexamer. Synthesized cDNA was used as template to perform 
PCR using primers for the full pTP gene obtained from NCBI (NC_001405.1 or AC_000008). Sense/antisense 
primer sequences are as follows: 5′-ATG GCC TTG AGC GTC AAC GATT-3′, 5′-CTA AAA GCG GTG ACG CGG 
G-3′. PCR products were ligated into pMD20-T vector (Takara, USA), which has a dT-overhang at the 3′ end. 
Then, PCR product in pMD20-T vector was cloned into the expression vector pCDNA3.1-hygro(+) (Invitrogen, 
Carlsbad, CA, USA) at the BamHI and XbaI sites. To improve expression of the pTP gene, Kozak sequence 
(GCC ACC ) was inserted in front of the pTP gene by annealing. Expression of pTP protein was confirmed by 
western blotting using pTP antibody. Next, the pTP gene with Kozak sequence was subcloned into an adenoviral 
shuttle vector, pVAX1-3484-CMVp-ΔE1B, at the HindIII and SalI-blunted sites. The adenoviral shuttle vector, 
pVAX1-3484-CMVp-ΔE1B-Kozak-pTP, was linearized by PmeI digestion. The adenoviral vector dl324-BstBI 
was linearized by Bsp119I digestion, and the two linearized vectors were co-transformed into E. coli BJ5183 cells 
for homologous recombination. The following virus amplification step was the same as for other adenoviruses.
Generation of both Daxx‑specific RNA and pTP‑expressing oncolytic adenovirus. To gener-
ate both Daxx-specific RNA and pTP-expressing oncolytic adenovirus, linearized both pSP72ΔE3-H1-shDaxx 
shuttle vector by XmnI and dl324-BstBI adenoviral vector by SpeI were co-transformed into E. coli BJ5183 cells 
for homologous recombination. Then dl324-BstBI-H1-shDaxx after linearization by Bsp1191 was homologously 
recombined again with adenoviral shuttle vector, pVAX1-3484-CMVp-ΔE1B-Kozak-pTP after linearization by 
PmeI. The final adenoviral plasmid, dl324-3484-CMVp-ΔE1B-Kozak-pTP-H1-shDaxx, was then digested with 
PacI and transfected into HEK-293 cells to generate tumor-selective replication-competent adenovirus. The fol-
lowing virus amplification step was the same as for other adenoviruses.
IVa2 cloning. For the cloning of adenoviral IVa2, adenoviral backbone containing IX gene was used as a 
template for the IVa2 PCR without 5′ end gene (ATG GAA ACC AGA G) sense primer 5′-TTA TTT AGG GGT TTT 
GCG CGCG-3′, antisense primer 5′-GGC GAA GAC CGG CAG CGC TT-3′ resultant PCR product was inserted 
into pDrive cloning vector (Qiagen, Hilden, Germany) and selected clones with reverse orientation by sequenc-
ing analysis. Then, the annealed DNA fragment designed for the complete construct of IVa2 was added to the 
HindIII/MscI digested pDrive-IVa2 without 5′ end gene.
The following sequences were prepared for the annealing and adding to IVa2 without 5′ end. Top strand 
was 5′-AGC TTA TGG AAA CCA GAG GGC GAA GAC CGG CAG CGC TTC AGC ACC AGC AGG ACC AGC CTC 
AAG CGC ACC CTG G-3′. Bottom strand was 5′-CCA GGG TGC GCT TGA GGC TGG TCC TGC TGG TGC TGA 
AGC GCT GCC GGT CTT CGC CCT CTG GTT TCC ATA-3′. Finally, the cloned IVa2 in pDrive cloning vector was 
subcloned to HindIII/BamHI-predigested pcDNA3.1 hygro by digestion with HindIII/BamHI for the confirma-
tion of IVa2 expression.
Titration of virus particles. For calculating the amount of total virus particles, purified virus was dis-
sociated with 0.2% SDS in PBS (pH 7.2) for lysis of viral capsid before  titration29. Measurements of the optical 
density (OD) of diluted virus samples at wavelengths 260 and 280 nm using spectrophotometer were performed. 
For purified virus, the ratio of absorbance at 260 nm and 280 nm should be close to 1.3. The total virus particles 
were calculated by the following formula:
OD260 reading × dilution factor × 1.1 × 1012 particles = number of particles per mL. To calculate the amount 
of infectious virus particles, viral soup was obtained by freezing and thawing infected cells and supernatant three 
times followed by centrifugation to obtain the pellet. Viral soup or purified virus was serially diluted in the range 
of  10−2–10−12 and each 100 μl of dilutes were added to a 1 × 104 293A packaging cell. After 7 days of incubation 
at 37 °C, the number of wells showing cytopathic effect (CPE) in 293A were counted. The amounts of infectious 
virus particles were then calculated by the following formula:
Titer (TCID50/mL) = 10^(1 + 1 (counted wells − 0.5) TCID50/mL, to transform TCID50/ml in PFU/ml, Titer 
(PFU/ml) = 1 × 10^(TCID50/mL-0.7).
Calculation of the number of viral DNA copies. Following infection of same amount of each virus, 
cultured cell and media were harvested after 24 h of infection. Then, viral DNA after CsCl density gradient ultra-
centrifugation and Tris-dialysis of harvested viral soup was purified by Exgene Viral DNA/RNA kit (GeneAll, 
Seoul, Korea) as provided in protocol, and then measured absorbance at OD260 and OD280. Copy numbers 
were calculated by the formula which requires amount of DNA and length of template considering molecular 
weight. (The formula used is: number of copies = (ng * 6.022 × 1023)/(length * 1 × 109 * 650)).
Oncolytic assay for cytopathic effect (CPE). To compare the CPE of replication-competent adenovi-
ruses (Ad-3484-shNC, Ad-3484-shDaxx), cells were first plated to ~ 80% confluency into 24-well plates. They 
were infected with various multiplicities of infection (MOIs) of each adenovirus. After 48–72  h of infection 
depending on the time point of complete lysis at 0.1 MOI, the remaining cells on the plate were fixed with 4% 
paraformaldehyde for 30 min and stained with 0.05% crystal violet for 10 min.
Immunoblot analysis. Cells were lysed in 1× Laemmli lysis buffer (62.5  mM Tris, pH 6.8, 2% sodium 
dodecyl sulfate, 10% glycerol, 0.02% bromophenol blue). Proteins were separated by SDS-PAGE and electro-
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Figure 1.  Enhanced adenovirus production by oncolytic adenovirus armed with Daxx shRNA. (A) Scheme 
of E1B55K-deleted oncolytic adenovirus armed with scrambled RNA (Ad-3484-NC) or Daxx shRNA 
(Ad-3484-shDaxx). (B) Expression of Daxx protein after infection with Ad-3484-NC or Ad-3484-shDaxx at 
the indicated MOIs for 48 h in DU145 cells. (C) Endogenous Daxx protein levels in various human cancer 
cells. (D) Plaque-forming unit (PFU) titration assays of adenovirus produced by each human cancer cell line 
following Ad-3484-NC or Ad-3484-shDaxx infection at MOI 50 for 48 h with exchanged media after PBS 
washing. Error bars represent standard errors from three independent experiments. P values less than 0.05 
were considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001). (E) Crystal violet oncolytic assay 
of DU145 (left), U251N (middle), and A549 cells (right) following Ad-NC, Ad-shDaxx, Ad-3484-NC, or 
Ad-3484-shDaxx infections at MOIs between 0 and 10 for 72 h. All cells remaining on plates were fixed with 4% 
paraformaldehyde and stained with 0.05% crystal violet.
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transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). After blocking 
each membrane (5% non-fat dry milk in TBS–Tween-20 (0.1%, v/v) at room temperature for 1 h, the mem-
brane was then incubated with the primary antibody (diluted according to the manufacturer’s instructions) for 
2  h ~ overnight depending on the antibody. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit or 
IgG was used as a secondary antibody. Immunoreactive proteins were visualized by chemiluminescence (ECL; 
Thermo Fisher Scientific, Waltham, MA, USA). The images of the original blots are available within supple-
mentary information file. Many original blots were cut prior to hybridization with antibodies to have the same 
experimental condition as much as possible and for convenience’ sake if the molecular size of expected proteins 
are clearly different, for example Daxx and caspase 8.
Immunohistochemistry (IHC). For IHC, tumor tissues of two mice per group after 7 days of third virus 
injection were extracted after  CO2 euthanasia. Then, they were fixed for 24 h in 10% formaldehyde, and embed-
ded in paraffin. Tissue sections were deparaffinized twice with xylene for 10 min and were rehydrated using 
a graded alcohol series. After antigen retrieval, the sections were permeabilized with 0.5% PBX (0.5% Triton 
X-100 in PBS) for 30 min and washed three times with PBS. After blocking for 1 h with 5% BSA, the sections 
with primary antibodies were incubated overnight at 4 °C. Primary Antibody Enhancer (Thermo Fisher Scien-
tific) and horseradish peroxidase Polymer (Thermo Scientific) were used for signal amplification. To develop the 
colored product, a mixture of DAB (3,3′-diaminobenzidine) Plus Chromogen and DAB Plus Substrate (Thermo 
Fisher Scientific) was added for 5 min. After washing with PBS, 20% hematoxylin counterstain was added for 
2–5 min to stain the nuclei. After dehydration and clearing twice in xylene, the tissue sections were coverslipped 
with mounting media (xylene:mount = 1:1) for microscopy.
Animal study. Animal study was carried out in compliance with the ARRIVE guidelines as follows. Animal 
studies were conducted following approved protocol (2018-0138) established by Yonsei University Health Sys-
tem’s Institutional Animal Care and Use Committee (IACUC) in accordance with the guidelines of the Animal 
Welfare Act and the Guide for the Care and Use of Laboratory Animals. After receiving the approval, eighty 
5-week-old male BALB/c athymic nude mice, weighing around 20 g, were obtained from OrientBio (Seongnam, 
Korea). All mice were housed for 1 week for a period of adjustment, and free feeding to food (PicoLab Rodent 
diet 20 5053) and purified water by reverse osmosis in individually ventilated cages were provided at a tempera-
ture of 21 ± 0.2 °C, humidity of 50 ± 10%, and a 12/12-h light/dark cycle. The maximum caging density was five 
mice and aspen chip after autoclave was used as bedding. To generate a xenograft tumor model, each of 1 × 107 
A549 or DU145 cancer cells were injected with Matrigel into the subcutaneous abdominal region of mice. When 
the tumors reached an average size of 100–120  mm3, 1 × 109 plaque forming unit (PFU) of each adenoviruses 
diluted in 50 μl PBS or PBS alone was intratumorally injected into the nude mice. Each mice group with similar 
average and standard deviation values of tumor size was separated (n = 7 per group). The adenoviruses injected 
were Ad-3484-NC, Ad-3484-shDaxx, Ad-3484-pTP, Ad-3484-pTP-shDaxx. Intratumoral injection was repeated 
every other day for a total of three injections. Five mice per group were used for the tumor size measurement, 
and two mice per group were used for the immunohistochemistry. Regression of tumor growth was assessed by 
measuring the length (L) and width (W) of tumors. Tumor volume was calculated using the following formula: 
Volume  (mm3) = 0.52 × L × W2.
Statistical analysis. Data are presented as the mean ± standard error of mean (S.E.M.). Differences between 
groups were examined using unpaired two-tailed t tests. P values were calculated using GraphPad Prism version 
6.0 (Systat Software Inc.). P < 0.001, P < 0.01 or P < 0.05 was considered statistically significant. All experiments 











































































Figure 2.  Increased viral infectivity by Daxx downregulation. (A) Western blot analysis for the detection 
of viral late gene products was performed in a variety of cancer cells as well as 293A cells infected with 
Ad-3484-NC or Ad-3484-shDaxx at 50 MOI for 48 h. The numbers indicate the relative band intensity of 
Ad-3484-shDaxx to control (Ad-3484-NC) after band intensities were measured with a densitometer. (B) 
Estimation of viral DNA copy number after infection with Ad-3484-shDaxx at 10 MOI for 24 h in 293A cells. 
After infection for 24 h, cultured cells and media were harvested. Purified DNA (CsCl gradient and Tris-dialysis 
of virus soup) was measured at OD260 and OD280 for copy-number calculations. Error bars represent standard 
errors from three independent experiments. P values less than 0.05 were considered statistically significant 
(*P < 0.05). (C) Virus particle estimation. After CsCl gradient and Tris-dialysis purification of the virus soup 
from 293A cells following infection with the same amount of each oncolytic adenovirus (Ad-3484-NC and 
Ad-3484-shDaxx), total virus particles (VP/ml) were calculated by measuring absorbance at OD260 (left) and 
the amounts of infectious virus particles were successfully calculated by TCID50 titration assays in 293A cells 
using plaque-forming units (PFU/ml) (right). Error bars represent standard errors from three independent 
experiments. P values less than 0.05 were considered statistically significant (*P < 0.05). (D) Infectious viral 
particles were estimated after transfection of pcDNA3.1-IVa2 followed by oncolytic control adenovirus in 
various HCC. Error bars represent standard errors from three independent experiments. P values less than 0.05 
were considered statistically significant (*P < 0.05).
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Results
Daxx has been previously reported to be a negative regulator of adenovirus replication, suggesting that adeno-
virus has evolved to mediate proteasomal degradation of Daxx protein using viral proteins such as E1B55K and 
 E4orf618,19. Although E1B55K-deleted oncolytic adenovirus, which selectively replicates in cancer cells that have 
mutant or p53-null status, is useful in terms of selectivity, it cannot induce proteasomal degradation of Daxx. 
Therefore, Daxx levels in cancer cells remain high after infection by E1B55K-deleted oncolytic adenovirus. 
Downregulation of Daxx could be helpful to increase viral production, we therefore constructed E1B55K-deleted 
oncolytic adenovirus armed with Daxx shRNA (Ad-3484-shDaxx). To confirm that Daxx was downregulated, 
levels of Daxx protein were assessed following infection either by Ad-3484-shDaxx or E1B55K-deleted oncolytic 
adenovirus armed with scrambled RNA (Ad-3484-NC) (Fig. 1A). Daxx protein levels decreased depending on 
Ad-3484-shDaxx multiplicity of infection (MOI), but not for Ad-3484-NC (Fig. 1B), implying that sequence-
specific Daxx downregulation occurred. Cellular Daxx protein showed various levels of expression in human 
cancer cells (Fig. 1C). To quantify infectious virus particles produced by Ad-3484-shDaxx compared to Ad-
3484-NC, a 50% tissue culture infective dose (TCID50) titration assay was performed using viral soup obtained 
from both cancer cell lines and the 293 adenovirus packaging cell line infected with 50 MOI (0.1 MOI for 293 
cells) Ad-3484-shDaxx and Ad-3484-NC, respectively. In all of the cancer cell lines examined, titrations showed 
significant increases (2.5–7.5 fold) in virus production for Ad-3484-shDaxx compared to Ad-3484-NC, and this 
viral production range was not related to p53 status. For example, A549 and SK-Hep1 cells (wild-type p53) pro-
duced relatively higher amount of virus, whereas Hep3B and BX-PC3 cells (mutant p53) produced relatively lower 
amounts of virus (Fig. 1D). Next, oncolytic assays were performed to confirm whether the increased production 
of virus progeny by Ad-3484-shDaxx was the main contributor to increased cell lysis in the various cancer cells 
rather than the cellular effects of Daxx downregulation. Increased cell death was observed with Ad-3484-shDaxx 
virus at 1 MOI, but not with the replication-deficient Ad-shDaxx (Fig. 1E). These results demonstrated that 
increased cell lysis was caused by greater virus production, not by the cellular effects of Daxx downregulation.
Daxx downregulation increased infectious virus particle rather than total virus particles. Ade-
noviral protein levels after viral infection in various cell lines were investigated after Daxx downregulation. 
Unexpectedly, adenoviral protein levels of capsid proteins (e.g., Hexon, Penton, protein V, and VI) and protein 
VII did not differ significantly between cells infected with Ad-3484-NC or Ad-3484-shDaxx (Fig. 2A). Although 
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protein (an early-gene transcription product involved in viral replication) and IVa2 protein (known to be among 
the late-gene transcription products L422K, L433K, and IVa2 involved in viral DNA  packaging30–33) increased 
following Ad-3484-shDaxx infection in the various cells (Fig.  2A). Taken together, these results indicate an 
increase in gene copies by Daxx downregulation (Fig. 2B), and an increase in infectious viral particles without 
increasing adenoviral protein levels or total virus particles with Ad-3484-shDaxx compared to Ad-3484-NC 
amplified from 293A cells (Fig. 2C). Next, we tested the possibility of increased viral packaging via increased 
IVa2 levels induced by Daxx downregulation. To test this, we used exogenous IVa2 gene expression in various 
hepatocellular carcinoma followed by oncolytic control adenovirus (Ad-3484-NC) challenge. Figure 2D shows 
that infectious viral particles were significantly increased by exogenous IVa2 expression.
pTP increased progeny virus production. Even though Daxx downregulation increased infectious viral 
particle, it was important to assess other factor(s) that could enhance adenovirus replication, in order to maxi-
mize its oncolysis efficacy. Experiments designed to increase the expression of pTP, a protein required for initiat-
ing viral gene replication into adenovirus  structures7, were then performed. pTP has been shown to promote 
post-infection initiation of viral gene replication by binding with cellular factors NFI and Oct-17–10,34. E1B55K-
deleted oncolytic adenovirus constructed with the full gene coding for pTP (Ad-3484-pTP) was generated 
(Fig. 3A), and pTP expression was confirmed using an antibody that recognized the pTP epitope HNRDMTG-
GVFQLR (Fig. 3B). pTP overexpression led to increased E1A expression in various cancer cells (Fig. 3C,D), as 
well as increases in other viral proteins, including viral genome packaging-related proteins. As a result, viral 
genome increases and increases in total virus particles were seen, concomitant with increased infectious viral 
particle (Fig. 3E,F). Using a variety of cancer cells, this pTP overexpression resulted in increased infectious viral 
particle approximately 2.5–6 fold (Fig. 3G); more infectious viral particle in most of the examined cancer cell 
types than that seen with Ad-3484-shDaxx. As demonstrated in Fig. 3D, the expression of IVa2 (induced by pTP 
overexpression) increased more compared to other packaging-related proteins (L422K and L433K) and may 
have also increased packaging efficiency.
Both pTP overexpression and Daxx downregulation significantly increased. infectious viral 
particle. We next examined the effects of combining pTP overexpression with Daxx downregulation on 
virus production in vitro. E1B55K-deleted oncolytic adenovirus expressing both pTP and Daxx shRNA (Ad-
3484-pTP-shDaxx) was generated (Fig. 4A), and pTP expression and Daxx downregulation were confirmed. 
Total viral particle and infectious viral particle were compared between Ad-3484-NC and Ad-3484-pTP-
shDaxx, and both were found to be significantly increased with pTP expression and with Daxx downregulation 
(Fig. 4B), while the expression pattern of viral proteins, including E1A, was almost the same with pTP expres-
sion only (Fig. 4C). Overall, infectious viral particle increased in the order of shDaxx < pTP < shDaxx/pTP in the 
various cancer cells examined (Fig. 4D), resulting in enhanced tumor-cell lysis (Fig. 4E). We also investigated 
whether viral production was preceded by apoptotic death or autophagic death, and the timing of autophagy/
apoptosis induced by shDaxx or pTP from various cancer cells (Fig. 4F). Minor autophagy or apoptosis occurred 
after Daxx downregulation or pTP overexpression, depending on the p53-related cancer cell types. This minor 
autophagy likely originated from our own viral structure of E1B-deleted oncolytic adenovirus. Piya et al. also 
reported that E1B19K was linked to beclin 1-mediated autophagic cell  death28,35. This inhibited or enhanced 
autophagy, compared to untreated infections, also showed a tendency for increased or decreased infectious viral 
particle production, respectively (Fig. 4G), and a negative correlation between the induction of autophagic cell 
death and virus replication, a contradictory result to Rodriguez-Rocha et al.28. Unexpectedly, cell viability was 
also decreased even after treatment with autophagy inhibitor (3-MA) (Fig.  4H), suggesting either enhanced 
Figure 3.  Enhanced production of progeny virus by introduction of the precursor terminal protein (pTP) gene. 
(A) Scheme of pTP-overexpressing E1B55K-deleted oncolytic adenovirus. (B) Expressions of pTP protein in 
DU145 cells after Ad-3484-pTP infection at indicated MOIs for 48 h. (C) Western blot analysis for detection of 
protein levels, including Adenovirus type 5, in A549 and Hep3B cells infected using various MOIs of Ad-3484-
pTP for 48 h. (D) Western blot analysis for detection of protein levels, including adenovirus type 5, in various 
cancer cells as well as in 293A cells infected with 10 MOIs of Ad-3484-pTP for 48 h. The numbers indicate 
the relative band intensity of Ad-3484-pTP to control (Ad-3484-NC) after band intensities were measured 
with a densitometer. (E) Estimation of viral DNA copy number after pTP overexpression. After infection 
with Ad-3484-pTP at 10 MOI for 24 h in 293A cells, cells and media were harvested. Purified DNA after CsCl 
density gradient ultracentrifugation and Tris-dialysis of viral soup was measured at OD260 and OD280 for 
copy-number calculations. Error bars represent standard errors from three independent experiments. (F) 
After infections with the same amount of each oncolytic adenovirus (MOI 10 with Ad-3484-NC or Ad-3484-
pTP), and purification of virus following CsCl density gradient ultracentrifugation and Tris-dialysis of viral 
soup from 293A cells, total virus particles (VP/ml) were calculated by measuring absorbance at OD260 and 
plaque-forming units (PFU/ml), which indicates that the amounts of infectious virus particles were successfully 
calculated by TCID50 titration assays in 293A cells. Error bars represent standard errors from three independent 
experiments. P values less than 0.05 were considered statistically significant (*P < 0.05). (G) PFU titration assays 
of adenovirus produced by each human cancer cell line following Ad-3484-NC or Ad-3484-pTP infections at 
MOI 50 for 4 h, and incubations for 48 h with media exchanged after PBS washing. Adenovirus packaging cells 
(293A) were infected at MOI 0.1. Error bars represent standard errors from three independent experiments. P 
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cell death due to increased late viral lysis due to blocked autophagy, or enhanced cell death due to increased 
autophagy by rapamycin. Curiously, increased infectious viral particle production and decreased cell viability 
were also observed even in 3-MA-treated DU145 cells showing no LC3-II increase after Daxx downregulation 
(Fig. 4F–H), suggesting the possibility of LC3-independent  autophagy36. In addition, caspase-dependent apop-
tosis also had the tendency to inhibit viral production by shDaxx regardless of p53 status (Fig. 4I). Intriguingly, 
cell death was enhanced even under conditions of caspase inhibition, probably due to increased late viral lysis 
(Fig. 4J). On the other hand, wild-type p53 acetylation greatly increased with both Daxx downregulation (A549, 
SK-Hep1) and pTP overexpression (A549) (Fig. 4F). Here, p53 acetylation was used as a biomarker for p53 acti-
vation leading to apoptosis, as well as cell-cycle  arrest37,38. C646, a histone acetyltransferase p300 inhibitor acting 
as a p53 activation inhibitor, significantly increased viral production in p53 wild-type cancer cells (Fig. 4K), and 
decreased cell viability (Fig. 4L), suggesting that inhibition of p53 activation also enhanced cell death derived 
from viral lysis. Interestingly, decreased cell viability also occurred after treatment with a p53 acetylation inhibi-
tor in p53 mutant DU145 cells (for reference, Hep3B cells are p53 null) which showed no increase of p53 acetyla-
tion with Daxx downregulation (Fig. 4F), possibly through p300 inhibition acting like an inducer of apoptosis 
in prostate cancer  cells39.
Both pTP overexpression and Daxx downregulation effectively suppressed tumor growth. To 
confirm the antitumor effects of increasing virus production by pTP overexpression and Daxx downregulation, 
we performed in vivo experiments in xenograft animal models using Hep3B and A549 cell lines. Effective tumor 
suppression was observed in the Ad-3484-pTP-shDaxx group compared to the Ad-3484-NC group, suggesting 
that efficient virus production resulted in tumor regression in vivo (Fig. 5A,B). The immunohistochemical data 
suggested that the combination of pTP and Daxx downregulation was more effective for virus replication than 
in the single groups (Ad-3484-pTP or Ad-3484-shDaxx), leading to enhanced tumor suppression. Interestingly, 
Figure 4.  Enhanced virus production by both pTP and Daxx shRNA expressing E1B55K-deleted oncolytic 
adenovirus (Ad-3484-pTP-shDaxx). (A) Scheme of pTP and Daxx shRNA-both expressing E1B55K-deleted 
oncolytic adenovirus. (B) Virus particle amounts were determined after purification through a CsCl gradient 
and Tris-dialysis of virus soup from 293A cells. Following infection with the same amount of infectious 
oncolytic adenovirus (Ad-3484-NC and Ad-3484-pTP-shDaxx), total virus particles (VP/ml) (left) and plaque-
forming units (PFU/ml) (right) were calculated. Error bars represent standard errors from three independent 
experiments. P values less than 0.05 were considered statistically significant (**P < 0.01). (C) Western blot 
analysis for the detection of protein levels, including adenovirus type 5, from DU145 cells infected with 10 MOI 
of Ad-3484-NC, Ad-3484-shDaxx, Ad-3484-pTP, or Ad-3484-pTP-shDaxx for 48 h. (D) PFU titration assays 
of adenovirus produced by each human cancer cell line following Ad-3484-NC, Ad-3484-shDaxx, Ad-3484-
pTP, or Ad-3484-pTP-shDaxx infections at MOI 50 for 4 h, and incubation for 48 h with media exchanged 
after PBS washing. Adenovirus packaging cells (293A) were infected at MOI 0.1. Error bars represent standard 
errors from three independent experiments. (E) Oncolytic assays of various cancer cells (DU145, U251N, A549, 
Hep3B, and SK-Hep1) infected with Ad-3484-NC, Ad-3484-shDaxx, Ad-3484-pTP, or Ad-3484-pTP-shDaxx 
at MOIs between 0 and 10, for 72 h. All cells remaining on the plates were fixed with 4% paraformaldehyde 
and stained with 0.05% crystal violet. (F) Western blot analysis for detection of caspase 8, 9, LC3A/B-I, II, p53 
and acetylated p53 (Lys382) protein levels in various cancer cells infected with 10 MOIs of Ad-3484-NC or 
Ad-3484-shDaxx or Ad-3484-pTP for each indicated time. The numbers indicate the relative band intensity 
of infected samples for each indicated time to control (0 h) after band intensities were measured with a 
densitometer. (G) Plaque-forming unit (PFU) titration assays of adenovirus in various cancer cells treated with 
autophagy inhibitor (3-MA 10 mM) or autophagy enhancer (rapamycin 50 nM) for 44 h after 4 h of infections 
with 10 MOIs of Ad-3484-NC, Ad-3484-shDaxx, or Ad-3484-pTP. PFU ratios mean that viral titer of 3-MA or 
rapamycin-treated cancer cells after infection NC, shDaxx or pTP virus divided by viral titer of untreated cancer 
cells after infection NC, shDaxx or pTP virus respectively. Error bars represent standard errors from three 
independent experiments. NC, Ad-3484-NC; shDaxx, Ad-3484-shDaxx; pTP, Ad-3484-pTP (H) Cell viability in 
various cancer cells treated with autophagy inhibitor (3-MA 10 mM) or autophagy enhancer (rapamycin 50 nM) 
for 44 h after 4 h of infections with 10 MOIs of Ad-3484-shDaxx. Cell viability was estimated by trypan blue 
exclusion. Error bars represent standard errors from three independent experiments. (I) Plaque-forming unit 
(PFU) titration assays of adenovirus in various cancer cells treated with pan caspase inhibitor (Z-VAD-FMK 
10 μM) for 44 h after 4 h of infections with 10 MOIs of Ad-3484-shDaxx Error bars represent standard errors 
from three independent experiments. P values less than 0.05 were considered statistically significant (*P < 0.05). 
(J) Cell viability in various cancer cells treated with pan caspase inhibitor (Z-VAD-FMK 10 μM) for 44 h after 
4 h of infections with 10 MOIs of Ad-3484-shDaxx. Cell viability was estimated by trypan blue exclusion. Error 
bars represent standard errors from three independent experiments. P values less than 0.05 were considered 
statistically significant (***P < 0.001). (K) Plaque-forming unit (PFU) titration assays of adenovirus in various 
cancer cells treated with histone acetyltransferase inhibitor (C646 25 μM) for 44 h after 4 h of infections with 
10 MOIs of Ad-3484-shDaxx. Error bars represent standard errors from three independent experiments. P 
values less than 0.05 were considered statistically significant (*P < 0.05; **P < 0.01). (L) Cell viability in DU145, 
A549 and SK-Hep1 treated with histone acetyltransferase inhibitor (C646 25 μM) for 44 h after 4 h of infections 
with 10 MOIs of Ad-3484-shDaxx. Cell viability was estimated by trypan blue exclusion. Error bars represent 
standard errors from three independent experiments. P values less than 0.05 were considered statistically 


















































































































































































































































































































































































































































Figure 5.  Tumor size measurements and immunohistochemical images of tumors. Hep3B cells (A) or A549 cells (B) in Matrigel were 
injected subcutaneously in the abdominal region of BALB/c athymic nude mice, and intratumoral injections of PBS, or of each virus 
indicated, were repeated every other day for a total of three injections. Tumor volume was measured and calculated on the indicated 
days using the following formula: Volume  (mm3) = 0.52 × (Length) × (Width)2 (n = 5 per group) (upper). Error bars represent standard 
error from five mice in each experimental group. The asterisk indicates a significant difference between each comparative group 
(*P < 0.05; **P < 0.01). Tumor tissues after euthanasia from each group (n = 2 per group) for immunohistochemistry were harvested 
7 days following virus infections. Adenovirus 5, pTP or Daxx primary antibodies were incubated overnight at 4 °C on tissue slides. 
Images were obtained by light microscopy (200×). (lower).
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tumor regression was greater in A549, a p53 wild-type tumor after shDaxx infections than after pTP infections, 
suggesting that apoptotic death (caspase activation + p53 activation) as well as autophagy induction were more 
effective in diminishing tumor sizes in functional p53 tumor types despite sacrificing viral production. In sum-
mary, Fig. 6 provides a schematic diagram of enhanced viral production and anti-tumoral effect by a combina-
tion of Daxx downregulation, and pTP upregulation, in E1B55K/19K deleted oncolytic adenovirus.
Discussion
In this study, we have shown enhanced virus production by silencing Daxx, by overexpressing pTP, or in com-
bination. To improve the efficacy of oncolytic adenovirus therapy in cancer patients, adequate virus replication 
and production of infectious progeny virus for cell lysis (oncolysis) in tumors, are indispensable. In previous 
clinical trials and in vivo tests, most viruses deteriorated in tumors, resulting in failures to reduce tumor mass. 
There were several reasons for these: limited virus delivery to adjacent tumor cells, despite reaching the tumor 
site, because of abundant extracellular matrix and stromal cells; insufficient virus replication in tumor cells; high 
interstitial fluid pressure; and host antiviral defense  systems40–43. Notwithstanding changes to current OV therapy 
to include antitumor immune-modulating agents, attention to the prerequisites for virus production could be 
still one of the most effective ways to improve antitumor  efficacy40. Here, we studied the control of cellular- and/
Figure 6.  Schematic diagram of enhanced viral production and anti-tumoral effect by a combination of Daxx 
downregulation, and pTP upregulation, in E1B55K/19K deleted oncolytic adenovirus. pTP upregulation greatly 
increased viral production, while Daxx downregulation increased mainly infectivity, but not total virus particles. 
Additionally, Daxx downregulation induced stronger apoptotic cell death than pTP expression did in tumor 
cells with wild type p53, resulting in an enhanced anti-tumoral effect. This suggests that the combination of 
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or viral-factor expression related to virus replication for the purpose of overcoming insufficient virus produc-
tion, and investigating the different mechanisms of viral production by Daxx downregulation and pTP expres-
sion. Daxx, a repressor of virus replication, remains at high levels in human cancer cells after E1B55K-deleted 
adenovirus infection, because viral protein E1B55K, the major component of E3 ligase complex with E4orf6, is 
required for proteasomal degradation of Daxx  protein18. Schreiner et al. explained the mechanism by which Daxx 
protein represses viral replication with  ATRX25. Blocking Daxx/ATRX complex assembly, by E1B55K-mediated 
proteasomal degradation of Daxx protein, may be required for the efficient transcription of adenoviral genes. We 
previously demonstrated that silencing Daxx encouraged adenovirus early-gene transcription that was required 
for viral DNA  replication7, but this silencing of Daxx was not sufficient to increase intermediate-early or late viral 
gene transcription products. In addition to enhance direct viral replication, Daxx downregulation was found to 
promote both autophagy and  apoptosis17,26. Here, we investigated the possibility that both autophagy and apop-
tosis were indispensable for efficient virus production. Autophagy may generate nutrients that can be used for 
producing viral  progeny28, and apoptotic cell death plays a central role in the timely release of progeny virus from 
infected cells, but also in host defenses by blocking viral expansion at initial stages of  infection44. It is reasonable 
to suppose that many viruses have evolved mechanisms to either inhibit or activate host-cell death depending 
on their needs. This means that, depending on the circumstances, inhibition of apoptosis may sometimes allow 
viruses to optimize replication and progeny synthesis by prolonging the infected cell’s life, otherwise host-cell 
apoptosis would release progeny virions. For example, maximal virus production is very dependent on timing; 
earlier cell death inhibited sufficient viral production, while later cell death induced adequate viral release. For 
our experimental conditions, Daxx downregulation and/or pTP overexpression increased viral production during 
various types of cancer-cell death and decreased viral production efficiency to some extent (Fig. 4).
In addition, for the E1B55K-deficient shDaxx downregulation experiments, p53 functionality (A549 cells with 
wild-type p53) was necessary for efficient tumor regression, supporting the view that shDaxx downregulation 
with functional p53 enhances apoptosis, promotes adenoviral replication, and increases late viral gene  expression5 
rather than the competing view that successful adenovirus replication requires inactivation of p53. The present 
results have also shown that the timing of cellular apoptosis and autophagy are very important for adequate viral 
production; late death for sufficient viral release, followed by tumor regression. pTP overexpression enhanced 
overall viral replication irrespective of p53 status, while shDaxx had a tendency to increase both viral produc-
tion in p53-mutant cancer cells, and apoptotic cell death in p53 wild-type cancer cells. The appearance of cell 
death that accompanied Daxx downregulation and/or pTP overexpression enhanced viral production is likely a 
negative byproduct of, rather than a promoter of, viral production, and maximal viral release might be achieved 
only by viral E4orf4-mediated  apoptosis45. Overall, it is more reasonable to regard the early activation of various 
types of cell death during virus replication simply as a host defense mechanism for combating viral  infection46. 
Thus, the timing of various types of cell death induced by viral oncolytic replication needs further investigation. 
pTP upregulation greatly increased viral production, while Daxx downregulation mainly increased infectivity, 
but not total virus particles. In addition, Daxx downregulation induced a stronger apoptotic cell death response 
in tumor cells with wild-type p53 than pTP expression did, resulting in an enhanced anti-tumoral effect. This 
suggests that Daxx downregulation combined with pTP upregulation in oncolytic adenovirus therapy could be 
an ideal cooperative pairing. Therefore, the combination of shDaxx and pTP could provide a very satisfactory 
antitumor influence on a variety of tumor types with different genetic backgrounds.
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